Antidepressant drugs and cardio-vascular system
DOI:
https://doi.org/10.12923/j.2084-980X/26.2/a.05Keywords:
depression, antidepressant drugs, cardio-vascular systemAbstract
Depression is becoming a more and more frequent problem in highly – developed countries. There exist many factors predisposing to the occurrence of the disease. To most commonly mentioned, are organic CNS damage, genetic factors, disorders in neurotransmitters, and hormone dysfunctions. The disease disturbs the functioning of many organs and systems, causing the increase in the risk of the progression of the coronary disease and venous thrombotic- embolic illness. Antidepressants constitute the heterogenic group in terms of their chemical structure and mechanisms of action. Today it is known that applying them indeed increases the risk of the development of disadvantageous changes in the cardio-vascular system. In this study, an attempt of synthetic analysis of the influence of medicines applied in the treatment of depression on cardiovascular diseases was undertaken.
References
1. Dennis A.T., Nassal D., Deschenes I. et al.: Antidepressant- induced ubiquitination and degradation of the cardiac potassium channel hERG. J. Biol. Chem., 286, 34413, 2011.
2. Dowlati Y., Herrmann N., Swardfager W.L., Reim E.K., Lanctot K.L.: Efficacy and tolerability of antidepressants for treatment of depression in coronary artery disease: a meta-analysis. Can. J. Psychiatry, 55(2), 91-99, 2010.
3. Elikowski W., Małek M., Żytkiewicz M.: Depresja i jej leczenie, a żylna choroba zatorowa: trzy przypadki zatorowości płucnej, Kardiologia Polska, 69, 6, 596-599, 2011.
4. Emamhadi M., Mostafazadeh B., Hassanijirdehi M.: Tricyclic antidepressant poisoning treated by magnesium sulfate: a randomized, clinical trial. Drug Chem. Toxicol., 35, 300, 2012.
5. Halaris A.: Comorbidity between depression and cardiovascular disease. Int. Angiol., 28:92–99, 2009.
6. Harvey M., Cave G.: Case report: successful lipid resuscitation in multi-drug overdose with predominant tricyclic antidepressant toxidrome. Int. J. Emerg. Med., 5-8, 2012.
7. Kramer D.B., Zimetbaum P.J.: Long-QT syndrome Kardiol. Rev., 19, 217, 2011.
8. Mavrides N., Nemeroff Ch.: Treatment of depression In cardiovascular disease, Depression and Anxiety, 00, 1-14, 2013.
9. Nemeroff C.B., Goldschmidt-Clermont P.J.: Heartache and heartbreak—the link between depression and cardiovascular disease. Nat. Rev. Cardiol., 9(9), 526-539, 2012.
10. Pozuelo L., Zhang J., Franco K., Tesar G., Penn M., Jiang W.: Depression and heart disease: what do we know, and where are we headed? Cleve Clin. J. Med., 76(1), 59-70, 2009.
11. Pużyński S.: Leki przeciwdepresyjne. Psychiatria, 59-103, 2003.
12. Smoller J.W., Allison M., Cochrane B.B., et al.: Antidepressant use and risk of incident cardiovascular morbidity and mortality among postmenopausal women in the women’s health initiative study. Arch. Intern. Med., 169(22), 2128-2139, 2009.
13. Taylor D., Meader N., Bird V., Pilling S., Creed F., Goldberg D.: Pharmacological interventions for people with depression and chronic physical health problems: systematic review and meta-analysis of safety and efficacy. Br. J. Psychiatry, 198, 179-188, 2011.
14. Wysokiński A., Orzechowska A., Strombek M., Gruszczyński W.: Zespół metaboliczny – przegląd piśmiennictwa. Psychiatria w Praktyce Ogólnolekarskiej, 7, 170-175, 2007.
15. Van Melle J.P., de Jonge P., Honig A., et al.: Effects of antidepressant treatment following myocardial infarction. Br. J. Psychiatry, 190, 460-466, 2007.
16. Van Neste E.G., Werbruggen W., Leysen M.: Deep vein thrombosis and pulmonary embolism in psychiatric settings. Eur. J. Psychiatry, 23, 19-30, 2009.
17. Zapalska-Pożarowska K., Szponar J., Tchórz M.: Severe tricyclic antidepressants poisonings – case study, Przegląd Lekarski, 69, 8, 621-623, 2012.
Downloads
Published
Issue
Section
License
Copyright (c) 2013 Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
